Plus Therapeutics, Inc.
PSTV
$5.50
-$0.03-0.54%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -24.80% | -2.15% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -24.80% | -2.15% | |||
| Cost of Revenue | -2.58% | 20.73% | |||
| Gross Profit | -16.71% | -51.49% | |||
| SG&A Expenses | 26.73% | 21.06% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 14.60% | 20.92% | |||
| Operating Income | -23.98% | -28.11% | |||
| Income Before Tax | -21.58% | -29.17% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -21.58% | -29.17% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -21.58% | -29.17% | |||
| EBIT | -23.98% | -28.11% | |||
| EBITDA | -25.48% | -27.06% | |||
| EPS Basic | -0.74% | -0.79% | |||
| Normalized Basic EPS | -0.76% | -0.78% | |||
| EPS Diluted | 0.56% | -2.11% | |||
| Normalized Diluted EPS | -0.76% | -0.78% | |||
| Average Basic Shares Outstanding | 20.68% | 28.16% | |||
| Average Diluted Shares Outstanding | 20.68% | 28.16% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||